Pipeline

ATA3431

ATA3431: Off-the-Shelf Allogeneic CD19/CD20 Program for B-Cell Hematological and Autoimmune Malignancies

- ATA3431 consists of allogeneic Epstein-Barr virus (EBV)-sensitized T cells that express a CD20/CD19 CAR construct
- The CD20-CD19 binding domains are oriented to optimize potency
- Dual targeting designed to address antigen escape and tumor variability
- ATA3431 manufacturing is based on clonally expanded EBV T cells, inherently having lower potential for alloreactivity
- 1XX signaling domain optimizes expansion and mitigates T-cell exhaustion
- ATA3431 CAR T cells have been designed for T-cell memory, expansion, and anti-tumor efficacy¹
- Preclinical data have demonstrated early evidence of antitumor activity, long-term persistence, and superior tumor growth inhibition compared to an autologous CD19/CD20 CAR T benchmark¹
- Academic program generated proof-of-principle for an earlier-generation allogeneic CD19 targeted CAR EBV T-cell construct in relapsed/refractory B-cell malignancies after stem cell transplant²
- IND targeted for 2025

Cha, S et al. Oral Presentation. ATA3431: Allogeneic CD19/CD20 Bispecific CAR EBV T Cells for the Treatment of B-Cell Malignancies. TCT 2024.
Curran KJ, et al. ASH 2023

ATA3219

ATA3219 is an allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, currently in clinical development, leveraging the EBV T-cell platform and features a next-generation 1XX co-stimulatory domain, memory phenotype, and unedited T-cell receptor.

Oncology

Program/Indication
Pre-clinical
Phase 1
Phase 2
Phase 3

Non-Hodgkin’s Lymphoma (NHL)
Phase 1
- ATA3219 is currently being investigated in a Phase 1 trial for subjects with relapsed/refractory B-cell Non-Hodgkin's Lymphoma. Initial clinical data anticipated Q4 2024 (NCT06256484).

Autoimmune

Program/Indication
Pre-clinical
Phase 1
Phase 2
Phase 3

Lupus Nephritis (LN)

Systemic Lupus Erythematosus (SLE) without lymphodepletion
Phase 1
- ATA3219 Phase 1 study initiation for subjects with lupus nephritis planned for Q4 2024. Initial clinical data expected in H1 2025 (NCT06429800).
- Initiation of ATA3219 cohort without lymphodepletion in systemic lupus erythematosus planned for Q4 2024, with initial clinical data expected in H2 2025.

Next-Generation CAR T Technology

Our preclinical pipeline is rapidly expanding with novel technologies and next-generation, multi-targeted CAR T immunotherapies thanks to our collaboration with Memorial Sloan Kettering Cancer Center.